[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9-methoxy-10,14,17,17-tetramethyl-12-(2-morpholin-4-ylethyl)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9-methoxy-10,14,17,17-tetramethyl-12-(2-morpholin-4-ylethyl)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
• 化学式: C₅₀H₆₆N₂O₁₄
• 分子量: 919.079
• InChiKey: OPIIJJPPFNOILK-HVOOWIBXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  66
• 可旋转键数：
  17
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  206
• 氢给体数：
  3
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  在 sodium hexamethyldisilazane 、 镍 、 氟化氢吡啶 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9-methoxy-10,14,17,17-tetramethyl-12-(2-morpholin-4-ylethyl)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
  参考文献：
  名称：

  Orally active docetaxel analogue

  摘要：

  To improve cytotoxicity of 10-deoxy-10-C-morpholinoethyl docetaxel analogues against various turner cell lines including resistant cells expressing P-glycoprotein (P-gp), we modified the 7-hydroxyl group to hydrophobic groups (methoxy, deoxy, 6,7-olefin, alpha -F, 7-beta -8-beta -methano, fluoromethoxy). Among these analogues. the 7-methoxy analogue showed the strongest cytotoxicity. This analogue showed potent activity against B16 melanoma BL6 in a vivo by oral administration. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00682-x

文献信息

• Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
  申请人：EnGeneIC Molecular Delivery Pty Ltd

  公开号：US11052157B2

  公开（公告）日：2021-07-06

  Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.

  将小分子化合物装载到完整的细菌衍生囊泡中，可增强操作和治疗优势。
• Combination with Bis(thiohydrazide amides) for treating cancer
  申请人：Koya Keizo

  公开号：US20080119440A1

  公开（公告）日：2008-05-22

  Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with radiotherapy.
• Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
  申请人：Williams Martin

  公开号：US20080176828A1

  公开（公告）日：2008-07-24

  Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.
• Treating melanoma with bis(thiohydrazide amides)
  申请人：McLeod Matthew

  公开号：US20080226588A1

  公开（公告）日：2008-09-18

  Disclosed herein are methods of treating lentigo maligna, superficial spreading malignant melanoma, acral lentiginous malignant melanoma or nodular malignant melanoma with bis(thio-hydrazide amides) represented by a formula selected from structural formulas (i)-(ix) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.
• Combination cancer therapy with bis(thiohydrazide) amide compounds
  申请人：Dahl Thomas A

  公开号：US20090137682A1

  公开（公告）日：2009-05-28

  A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g., Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R 1 -R 4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R 7 -R 8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.